NCI Research Specialist (Clinician Scientist) Award

项目摘要 我是一名儿科血液学家，肿瘤学家在丹L。邓肯综合癌症中心 儿科癌症计划（DLDCCC PCP），拥有儿科血液学双认证- 肿瘤学和临床药理学。我在发育方面有临床和研究专长 治疗剂、神经母细胞瘤和其他儿科实体瘤。我致力于成为一名 临床医生-科学家，在国家临床试验的发展中担任国家领导人， 在我的机构实施NCI临床试验，并为NCI临床试验做出贡献 通过参与科学审查和监测委员会建立网络。我的临床 研究兴趣集中在将新疗法引入早期临床试验， 神经母细胞瘤和其他儿科实体瘤患者，并减轻相关毒性 接受治疗 在PCP中，我是神经母细胞瘤项目的临床主任， 肿瘤计划和发展治疗学（DVL）计划的助理主任。 在这些角色中，我领导并实施了针对患有实体瘤的儿科患者的治疗性临床试验。 复发性或难治性儿童癌症患者的早期临床试验 疾病此外，我还为国家癌症研究所资助的儿童肿瘤学的国家领导层做出贡献。 集团（COG）和儿科早期临床试验网络（PEP-CTN）作为三个成员 指导委员会（癌症控制，神经母细胞瘤生物学和神经母细胞瘤）;委员会 两项治疗高危神经母细胞瘤患者的临床试验的成员; 正在进行的1期试验; PEP-CTN性能监测委员会成员;和研究中心 我所在机构PEP-CTN的PI。此外，我还指导年轻的调查人员， 机构和通过全国COG辅导计划。我每年出席并出席 COG秋季和春季会议我50%以上的精力都花在了PI上， 患者知情同意和入组活动，以及与我直接相关的行政责任 COG和PEP-CTN活动。

Project Abstract I am a Pediatric Hematologist-Oncologist at the Dan L. Duncan Comprehensive Cancer Center’s Pediatric Cancer Program (DLDCCC PCP), with dual board certifications in Pediatric Hematology- Oncology and Clinical Pharmacology. I have clinical and research expertise in developmental therapeutics, neuroblastoma, and other pediatric solid tumors. I am committed to a career as a clinician-scientist, serving as a national leader in the development of national clinical trials and the implementation of NCI clinical trials at my institution and contributing to NCI clinical trial networks through participation in both scientific review and monitoring committees. My clinical and research interests are focused on ushering novel therapies into early-phase clinical trials for patients with neuroblastoma and other pediatric solid tumors and mitigating toxicities associated with therapy. Within the PCP, I am the Clinical Director of the Neuroblastoma Program, Director of the Solid Tumor Program, and the Assistant Director of the Developmental Therapeutics (DVL) Program. In these roles, I lead and implement therapeutic clinical trials for pediatric patients with solid tumors and early-phase clinical trials for pediatric cancer patients with relapsed or refractory disease. In addition, I contribute to the national leadership of the NCI-funded Children’s Oncology Group (COG) and Pediatric Early Phase Clinical Trial Network (PEP-CTN) as a member of three steering committees (Cancer Control, Neuroblastoma Biology, and Neuroblastoma); a committee member for two clinical trials treating patients with high-risk neuroblastoma; Study Chair for an ongoing phase 1 trial; a member of the PEP-CTN Performance Monitoring Committee; and site PI for the PEP-CTN at my institution. Additionally, I mentor young investigators both at my institution and through the national COG mentoring program. I attend and present annually at the COGs Fall and Spring meetings. Greater than 50% of my effort is dedicated to PI responsibilities, patient consent and enrollment activities, and administrative responsibilities directly related to my COG and PEP-CTN activities.